March 14, 2022 12:20 PM EDT

Appeals court sides with Bristol Myers Squibb in years-long battle with investors over Opdivo fail

Nicole DeFeudis

Editor

Bristol Myers Squibb’s years-long court battle with investors over a failed Opdivo study is coming to a close. Second Circuit judges sided with the pharma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Appeals court sides with Bristol Myers Squibb in years-long battle with investors over Opdivo fail

Nicole DeFeudis

Editor

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Ap­peals court sides with Bris­tol My­ers Squibb in years-long bat­tle with in­vestors over Op­di­vo fail

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Appeals court sides with Bristol Myers Squibb in years-long battle with investors over Opdivo fail

Applied Therapeutics' rare disease drug gets a CRL

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M